Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs →
glpzoom

Orforglipron orforglipron

pronounced as (or for glip' ron)

Weight LossBy Eli Lilly· FDA-approved 2026New 2026

First once-daily oral non-peptide GLP-1. Brand-only, launching via LillyDirect at $149/month. No injection, no compounded versions.

Orforglipron delivery device illustration
Jump to section
Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.

Orforglipron vs Rybelsus

Both are daily oral GLP-1s. Rybelsus is the oral form of semaglutide (peptide, strict fasting rules); orforglipron is Lilly's non-peptide pill launching at $149/month.

OrforglipronRybelsus
Generic nameorforglipronsemaglutide (oral)
ManufacturerEli LillyNovo Nordisk
FDA statusFDA-approved 2026FDA-approved 2019
Clinical efficacy~14-15% mean body-weight reduction in Phase 3 (highest dose)—
Pivotal trialATTAIN-1 / ACHIEVE program—
Boxed warningYesYes
Full pageOrforglipron →Rybelsus →

Deep comparison: Orforglipron vs Rybelsus →

What is Orforglipron?

Orforglipron is Eli Lilly's once-daily oral GLP-1 receptor agonist, the first non-peptide GLP-1 to reach the US market. Unlike semaglutide (which requires either injection or a tightly-dosed oral peptide), orforglipron is a small molecule that survives digestion, so it can be taken as a simple daily pill without the strict fasting-and-water rules that oral semaglutide (Rybelsus) demands. It reached its FDA decision date April 10, 2026 and launches at $149/month through LillyDirect. There are no compounded versions, because it is a novel patented molecule.

How does Orforglipron work?

Same target as injectable GLP-1s — the GLP-1 receptor — but a non-peptide small-molecule structure. Activates GLP-1 signaling to slow gastric emptying, suppress appetite, and improve glycemic control. The oral, digestion-stable chemistry is the breakthrough: it expands GLP-1 therapy to patients who refuse injections.

Who can take Orforglipron?

Adults with obesity (BMI ≥30, or ≥27 with comorbidity) or type 2 diabetes, per the launch indications. Especially relevant for needle-averse patients who declined injectable GLP-1s. Same thyroid C-cell contraindication class as other GLP-1s.

How is Orforglipron taken?

Once-daily oral tablet, titrated upward over several weeks to manage GI side effects. No fasting or water-timing restrictions (unlike Rybelsus).

How much does Orforglipron cost?

$149/month via LillyDirect cash-pay at launch — meaningfully below branded injectable list prices. Insurance coverage will expand through 2026-2027 as formularies add it.

What side effects can Orforglipron cause?

GI side effects typical of the GLP-1 class: nausea, diarrhea, constipation, vomiting, especially during titration. Trial tolerability broadly comparable to injectable GLP-1s.

What if I miss a dose of Orforglipron?

Once-daily dosing. If a dose is missed, take it the same day if remembered; skip if it is nearly the next day. Do not double up.

How should Orforglipron be stored?

Store oral tablets at room temperature per the product label. Keep in original packaging away from moisture.

What if I overdose on Orforglipron?

Orforglipron is a non-peptide oral GLP-1; specific overdose data is limited. As with the injectable GLP-1s there is no specific antidote, and the same general approach applies: call US Poison Control at 1-800-222-1222 immediately, or go to the ER for severe hypoglycemia, persistent vomiting, dehydration, or altered mental status. The shorter daily-pill half-life means recovery should be faster than the weekly injectables, but supportive care is still required.

Related terms

Related topics

How to get it

  1. Take the eligibility quiz

    5 minutes of medical-history questions matched to the medication's FDA criteria. Free, no commitment.

  2. Submit ID + a recent photo

    Required by every legitimate US telehealth platform to verify identity and meet state prescribing rules.

  3. Async clinical review

    A licensed clinician in your state reviews your history and decides whether the medication is appropriate. Typically within 24-48 hours.

  4. Prescription ships

    If approved, the medication is sent from a partner pharmacy. Initial titration dose arrives in 3-7 days for most US states.

  5. Ongoing support

    Most programs include follow-up check-ins, dose adjustments, and side-effect support. Coverage varies by program.

Sources

Primary references this page draws from. We cite original sources so you can verify any claim.

  1. ManufacturerEli Lilly orforglipron media resources
  2. Clinical trialOrforglipron Phase 3 ATTAIN/ACHIEVE program (ClinicalTrials.gov)

More on Orforglipron

For clinicians: see the Orforglipron prescribing summary.

Share:
We may earn a commission when you click links to partners. Affiliate disclosure.